Xyzal

What Xyzal does

Xyzal is an over-the-counter oral antihistamine brand providing 24-hour allergy symptom relief for adults and children. The portfolio centers on two SKUs built around the active pharmaceutical ingredient levocetirizine dihydrochloride — a second-generation antihistamine: Adult Xyzal Allergy 24HR tablets (5mg) and Children's Xyzal Allergy 24HR oral solution (2.5mg/5mL) in Bubble Gum and Grape flavors. The brand is differentiated through clinical efficacy positioning including 45-minute onset, 24-hour duration with efficacy proven at hour 24 equivalent to hour 1, and a 5mg dose delivering comparable relief to 10mg cetirizine. Adult SKUs are offered in six count sizes (10 to 110 count), with the 110-count exclusive to warehouse club channels.

The brand is owned by Opella Healthcare Group SAS, a Sanofi subsidiary, and distributed in the US through Chattem, Inc., with corporate headquarters in Morristown, NJ and packaging operations at a zero-landfill Chattanooga, TN facility running on 100% renewable electricity. The XYZAL trademark is held by UCB. Go-to-market is omnichannel: nationwide retail through drug stores, grocery, mass merchandisers, and warehouse clubs; direct e-commerce via xyzal.com; an HCP sample ordering portal; and a multi-platform digital marketing presence spanning Facebook, Instagram, TikTok, YouTube, and X. Customer segments include adults with seasonal/perennial allergies (primary), parents of children ages 2+ with allergies, and athletes with allergy-related sleep disruption, the latter activated through the 2026 Boston Marathon sponsorship.

Revenue is generated exclusively through unit sales of OTC pharmaceutical products at retailer-discretionary pricing; brand-specific financials are not publicly disclosed. Marketing investment includes the "Nigel the Owl" brand mascot, "Storytime with Nigel" interactive children's content, allergy education content marketing, influencer partnerships (notably Peloton instructor Becs Gentry), event sponsorships, and a money-back guarantee program. The brand operates exclusively in the United States, with sustainability positioning (B Corp certification via Opella, TerraCycle packaging recycling partnership) increasingly central to its value proposition.

Name

Xyzal

Legal name

Chattem, Inc.

Website

https://xyzal.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Xyzal is an OTC oral antihistamine brand offering 24-hour allergy relief via levocetirizine-based tablets and children's liquid. Owned by Opella Healthcare Group (Sanofi subsidiary), it distributes through major US retail, online, and HCP channels for adult and pediatric allergy sufferers.

Ownership category

akta.pro rank

Product category

OTC Allergy Medication

NAICS

Pharmacies and Drug Retailers (456110)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Eye, Ear & Nasal Care (HLAIADAF)

akta.pro secondary industry

Pediatric OTC Medicines (HLAIADAL)

Keywords

• OTC allergy medication
• Antihistamine tablets
• Pediatric allergy relief
• Consumer healthcare products
• Levocetirizine formulations

Headquarters

HQ city

Morristown

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Operations, Personnel, Others

Revenue model

1. OTC Pharmaceutical Sales: Xyzal generates revenue through the sale of over-the-counter allergy relief medications. The products are sold through multiple retail channels including drug stores, grocery stores, mass merchandisers, warehouse clubs, and online. Pricing varies by retailer. Products are available without prescription at full prescription strength.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Xyzal is an over-the-counter allergy medication brand that sells 24-hour oral antihistamine products containing levocetirizine dihydrochloride. The portfolio includes adult 5mg tablets and a children's 2.5mg/5mL oral solution (Bubble Gum and Grape flavors) sold through U.S. retail, online retailers, and the brand's own e-commerce site, with healthcare professional samples distributed via a dedicated portal. Products are positioned for nighttime dosing to provide continuous relief from sneezing, runny nose, itchy/watery eyes, and itchy nose or throat in adults and children ages 2 and up.

Product overview

Xyzal is an over-the-counter allergy relief brand owned by Opella Healthcare Group (formerly Sanofi Consumer Healthcare). The portfolio consists of two main products: XYZAL® Allergy 24HR adult tablets (levocetirizine dihydrochloride 5 mg) and Children's XYZAL® Allergy 24HR liquid formula (levocetirizine dihydrochloride 2.5 mg/5 mL), available in Bubble Gum and Grape flavors for children ages 2 and older. Both products are positioned as nighttime allergy medications providing 24-hour continuous relief that does not fade. The brand also offers educational content through Storytime with Nigel, an interactive bedtime storytelling feature for children.

Differentiator

Problem solved

Functional benefit

Products and services

• XYZAL Allergy 24HR (Adult Tablets) Over-the-counter oral antihistamine tablets containing levocetirizine dihydrochloride 5mg, providing 24-hour continuous relief from sneezing, runny nose, itchy eyes, watery eyes, and itchy nose or throat. Designed for nighttime dosing in adults and children ages 6 and older. Onset in approximately 45 minutes, with efficacy maintained through hour 24. Available in 10-, 20-, 35-, 55-, 80-, 80-, and 110-count bottles across retail and online channels; the 110-count is exclusive to club stores.
• Children's XYZAL Allergy 24HR (Oral Solution) Over-the-counter oral antihistamine liquid for children ages 2 and older, containing levocetirizine dihydrochloride 2.5mg per 5mL. Available in Bubble Gum and Grape flavors, free of alcohol, sugar, and dyes, in 5 fl. oz. and 10 fl. oz. sizes. Taken at bedtime for 24-hour continuous allergy relief so children wake up symptom-free for school and activities.

Quantifiable outcome

• Works 50% faster than Claritin (45 min vs 75 min onset for first dose)
• +5 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Boston Marathon (Bank of America)flagshipGTM or Marketing Partner · 19 March 2026Xyzal became the first official allergy sponsor of the 2026 Boston Marathon presented by Bank of America. As part of the partnership, Xyzal maintains an on-site presence at the Bank of America Boston Marathon Expo from April 17-19, 2026, offering interactive booth experiences, product samples, and branded merchandise. Peloton instructor Becs Gentry serves as spokesperson and will meet attendees.
• TerraCyclecoreStrategic or Co-development PartnerXyzal has partnered with TerraCycle to enhance sustainability commitments by enabling recycling of packaging materials not accepted by local facilities. The partnership allows consumers to recycle Xyzal dosing cups, blisterpacks, and small tablet bottles through TerraCycle's free shipping program. As part of Opella's broader partnership, packaging from all Opella Healthcare Group brands can be included in the same shipping container.
• Becs GentrycoreGTM or Marketing PartnerBecs Gentry, Peloton instructor and marathon runner, serves as Xyzal spokesperson for the 2026 Boston Marathon sponsorship. She will meet attendees at the Xyzal booth during the marathon expo.
• Opella Healthcare Group (Parent Company)flagshipOthersXyzal is an over-the-counter allergy brand owned by Opella Healthcare Group. The makers of Xyzal are Certified B Corp. Products are distributed by Chattem, Inc. d/b/a Opella Healthcare Group.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Emerging players

• QlearQuil: Daytime and nighttime OTC allergy/sinus product line by Genexa. A newer, digitally-positioned brand competing for the same consumer segment as Xyzal with a clean-ingredient angle.
• Alavert: Loratadine-based OTC allergy relief brand marketed by Foundation Consumer Healthcare. Targets price-sensitive consumers in the same OTC category as Xyzal.
• Pataday: OTC ophthalmic antihistamine eye drops (olopatadine) for allergic conjunctivitis marketed by Alcon. Targets the ocular-allergy subset of the same consumer demographic that Xyzal addresses.

Direct peers

• Benadryl: First-generation OTC antihistamine (diphenhydramine) marketed by Kenvue. Xyzal explicitly differentiates on duration (24h vs 4–6h) and reduced sedation, positioning against Benadryl as a modern alternative.
• Nasacort Allergy 24HR: OTC intranasal corticosteroid (triamcinolone) for allergies, also distributed by Chattem/Opella, making it a sister-brand competitor within the same parent allergy portfolio.
• Allegra: OTC antihistamine brand (fexofenadine) also distributed by Chattem/Opella, making it a direct sister-brand competitor within the same parent company's US allergy portfolio.
• Flonase Allergy Relief: OTC intranasal corticosteroid (fluticasone) for allergic rhinitis marketed by Haleon. Competes for the same consumer allergy-symptom-relief budget via an alternative mechanism.
• Zyrtec: Direct OTC antihistamine competitor using cetirizine, the chiral parent compound of levocetirizine (Xyzal). Zyrtec is a top-three US OTC allergy brand and is the most pharmacologically comparable competitor.
• Claritin: Top OTC allergy brand (loratadine) marketed by Bayer. Xyzal explicitly positions against Claritin with faster onset claims (45 min vs 75 min), making it a primary head-to-head competitor.

Regional players

• Reactine: Cetirizine-based OTC allergy brand marketed by Kenvue in Canada. Pharmacologically analogous to Xyzal and a meaningful benchmark for North American second-generation antihistamine demand.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/XyzalAllergy
• YouTubeyoutube.com/channel/UCXREpOwlWkV6Wo-jnW1WTWA
• Facebookfacebook.com/Xyzal
• Instagraminstagram.com/xyzal
• TikToktiktok.com/@xyzalallergy
• LinkedInlinkedin.com/company/xyzal

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xyzal